176 related articles for article (PubMed ID: 29621897)
1. Current and potential targets for drug design in the androgen receptor pathway for prostate cancer.
Guddati AK
Expert Opin Drug Discov; 2018 Jun; 13(6):489-496. PubMed ID: 29621897
[TBL] [Abstract][Full Text] [Related]
2. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
Isaacsson Velho P; Carducci MA
Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor modulators: a review of recent patents and reports (2012-2018).
Fujii S; Kagechika H
Expert Opin Ther Pat; 2019 Jun; 29(6):439-453. PubMed ID: 31092069
[TBL] [Abstract][Full Text] [Related]
4. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
[TBL] [Abstract][Full Text] [Related]
5. Novel drugs targeting the androgen receptor pathway in prostate cancer.
Mateo J; Smith A; Ong M; de Bono JS
Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor antagonists: a patent review (2008-2011).
Mohler ML; Coss CC; Duke CB; Patil SA; Miller DD; Dalton JT
Expert Opin Ther Pat; 2012 May; 22(5):541-65. PubMed ID: 22583332
[TBL] [Abstract][Full Text] [Related]
7. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
Culig Z; Santer FR
Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
[TBL] [Abstract][Full Text] [Related]
8. Androgens in prostate cancer: A tale that never ends.
Hou Z; Huang S; Li Z
Cancer Lett; 2021 Sep; 516():1-12. PubMed ID: 34052327
[TBL] [Abstract][Full Text] [Related]
9. Regulation of prostate cancer by hormone-responsive G protein-coupled receptors.
Wang W; Chen ZX; Guo DY; Tao YX
Pharmacol Ther; 2018 Nov; 191():135-147. PubMed ID: 29909235
[TBL] [Abstract][Full Text] [Related]
10. Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer.
Singla N; Ghandour RA; Raj GV
Expert Opin Investig Drugs; 2019 Mar; 28(3):249-259. PubMed ID: 30649971
[TBL] [Abstract][Full Text] [Related]
11. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
12. Overcoming castration resistance in prostate cancer.
Tsao CK; Small AC; Galsky MD; Oh WK
Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
[TBL] [Abstract][Full Text] [Related]
13. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
14. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery.
Sakkiah S; Ng HW; Tong W; Hong H
Expert Opin Ther Targets; 2016 Oct; 20(10):1267-82. PubMed ID: 27195510
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.
Mostaghel EA; Plymate SR; Montgomery B
Clin Cancer Res; 2014 Feb; 20(4):791-8. PubMed ID: 24305618
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer?
Hoffman-Censits J; Fu M
Semin Oncol; 2013 Jun; 40(3):361-74. PubMed ID: 23806500
[TBL] [Abstract][Full Text] [Related]
17. Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.
Silberstein JL; Taylor MN; Antonarakis ES
Curr Urol Rep; 2016 Apr; 17(4):29. PubMed ID: 26902623
[TBL] [Abstract][Full Text] [Related]
18. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.
Chen Y; Clegg NJ; Scher HI
Lancet Oncol; 2009 Oct; 10(10):981-91. PubMed ID: 19796750
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence.
D'Antonio JM; Ma C; Monzon FA; Pflug BR
Prostate; 2008 May; 68(7):698-714. PubMed ID: 18302219
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
